The DOI matches its Crossref record; 87 of the 88 references it cites were found in a registry or an index.
A Progressive Mouse Model of Parkinson’s Disease: The Thy1-aSyn (“Line 61”) Mice
Open accessAbstract
Identification of mutations that cause rare familial forms of Parkinson's disease (PD) and subsequent studies of genetic risk factors for sporadic PD have led to an improved understanding of the pathological mechanisms that may cause nonfamilial PD. In particular, genetic and pathological studies strongly suggest that alpha-synuclein, albeit very rarely mutated in PD patients, plays a critical role in the vast majority of individuals with the sporadic form of the disease. We have extensively characterized a mouse model over-expressing full-length, human, wild-type alpha-synuclein under the Thy-1 promoter. We have also shown that this model reproduces many features of sporadic PD, including progressive changes in dopamine release and striatal content, alpha-synuclein pathology, deficits in motor and nonmotor functions that are affected in pre-manifest and manifest phases of PD, inflammation, and biochemical and molecular changes similar to those observed in PD. Preclinical studies have already demonstrated improvement with promising new drugs in this model, which provides an opportunity to test novel neuroprotective strategies during different phases of the disorder using endpoint measures with high power to detect drug effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The mouse model utilized in current study is known to reproduce most features of synucleinopathies, including neuropathology and deficits in motor and non-motor function (46).”
From LRRK2 mediates microglial neurotoxicity via NFATc2 in rodent models of synucleinopathies (2020) · cites this paper as [46]
Experimental — accuracy not yet measuredIn the citing paper
“Importantly, ASO (overexpressing a-synuclein under Thy1 promoter) mouse model of PD develops progressive deficits in motor function as well as in gut motility (182, 183).”
From The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology (2020) · cites this paper as [182]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WGCNA: an R package for weighted correlation network analysis
Langfelder, P., & Horvath, S. (2008) · BMC Bioinformatics · doi:10.1186/1471-2105-9-559 · Cited by 27,252
Harrison's Principles of Internal Medicine.
(1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-108-3-499_2 · Cited by 12,528
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Harrison's principles of internal medicine
(2008) · Choice Reviews Online · doi:10.5860/choice.46-0330 · Cited by 3,072
McGeer, P. L., Itagaki, S., Boyes, B. E., & McGeer, E. G. (1988) · Neurology · doi:10.1212/wnl.38.8.1285 · Cited by 2,990
Masliah, E., Rockenstein, E. M., Veinbergs, I., Mallory, M. E., Hashimoto, M., Takeda, A., Sagara, Y., Sisk, A., & Mucke, L. (2000) · Science · doi:10.1126/science.287.5456.1265 · Cited by 1,779
Braak, H., de Vos, R. A. I., Bohl, J., & Del Tredici, K. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2005.11.012 · Cited by 1,354
Brochard, V., Combadière, B., Prigent, A., Laouar, Y., Perrin, A., Beray-Berthat, V., Bonduelle, O., Alvarez-Fischer, D., Callebert, J., Launay, J.-M., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36470 · Cited by 1,172
Parkinson's disease: a dual‐hit hypothesis
Hawkes, C. H., Del Tredici, K., & Braak, H. (2007) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2007.00874.x · Cited by 1,021
Clinical progression in Parkinson disease and the neurobiology of axons
Cheng, H., Ulane, C. M., & Burke, R. E. (2010) · Annals of Neurology · doi:10.1002/ana.21995 · Cited by 1,012 · cited 1×
“Evidence from brain imaging studies suggests that axonal pathology precedes dopaminergic cell loss in PD [35].”
BackgroundPARIS (ZNF746) Repression of PGC-1α Contributes to Neurodegeneration in Parkinson's Disease
Shin, J.-H., Ko, H. S., Kang, H., Lee, Y., Lee, Y.-I., Pletinkova, O., Troconso, J. C., Dawson, V. L., & Dawson, T. M. (2011) · Cell · doi:10.1016/j.cell.2011.02.010 · Cited by 953
The scientific and clinical basis for the treatment of Parkinson disease (2009)
Olanow, C. W., Stern, M. B., & Sethi, K. D. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a1d44c · Cited by 947
Cools, R. (2006) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2005.03.024 · Cited by 903
Genetic Animal Models of Parkinson's Disease
Dawson, T. M., Ko, H. S., & Dawson, V. L. (2010) · Neuron · doi:10.1016/j.neuron.2010.04.034 · Cited by 866
Frequency of Bowel Movements and the Future Risk of Parkinson’s Disease
Abbott, R. D., Petrovitch, H., White, L. R., Masaki, K. H., Tanner, C. M., Curb, J. D., Grandinetti, A., Blanchette, P. L., Popper, J. S., & Ross, G. W. (2001) · Neurology · doi:10.1212/wnl.57.3.456 · Cited by 839
Association of olfactory dysfunction with risk for future Parkinson's disease
Ross, G. W., Petrovitch, H., Abbott, R. D., Tanner, C. M., Popper, J. S., Masaki, K., Launer, L. J., & White, L. R. (2007) · Annals of Neurology · doi:10.1002/ana.21291 · Cited by 739
Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease
Sulzer, D. (2007) · Trends in Neurosciences · doi:10.1016/j.tins.2007.03.009 · Cited by 602
Rate of cell death in parkinsonism indicates active neuropathological process
McGeer, P. L., Itagaki, S., Akiyama, H., & McGeer, E. G. (1988) · Annals of Neurology · doi:10.1002/ana.410240415 · Cited by 566
Neuropathology in Mice Expressing Human α-Synuclein
van der Putten, H., Wiederhold, K., Probst, A., Barbieri, S., Mistl, C., Danner, S., Kauffmann, S., Hofele, K., Spooren, W. P. J. M., Rüegg, M. A., et al. (2000) · Journal of Neuroscience · doi:10.1523/jneurosci.20-16-06021.2000 · Cited by 563
The α‐Synucleinopathies: Parkinson's Disease, Dementia with Lewy Bodies, and Multiple System Atrophy
Spillantini, M. G., & Goedert, M. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06900.x · Cited by 530
Neuropathology in mice expressing human alpha-synuclein
van der Putten, H., Wiederhold, K., Probst, A., Barbieri, S., Mistl, C., Danner, S., Kauffmann, S., Hofele, K., Spooren, W. P. J. M., Rüegg, M. A., et al. (2000) · PubMed Central · doi:10.5451/unibas-ep2767 · Cited by 505
Rockenstein, E., Mallory, M., Hashimoto, M., Song, D., Shults, C. W., Lang, I., & Masliah, E. (2002) · Journal of Neuroscience Research · doi:10.1002/jnr.10231 · Cited by 502
Early and Progressive Sensorimotor Anomalies in Mice Overexpressing Wild-Type Human α-Synuclein
Fleming, S. M., Salcedo, J. D., Fernagut, P., Rockenstein, E. M., Masliah, E., Levine, M. S., & Chesselet, M. (2004) · Journal of Neuroscience · doi:10.1523/jneurosci.3080-04.2004 · Cited by 477
Edwards, T. L., Scott, W. K., Almonte, C., Burt, A., Powell, E. H., Beecham, G. W., Wang, L., Zuchner, S. L., Konidari, I., Wang, G., et al. (2010) · Annals of Human Genetics · doi:10.1111/j.1469-1809.2009.00560.x · Cited by 471
Priorities in Parkinson's disease research
Meissner, W. G., Frasier, M. A., Gasser, T., Goetz, C. G., Lozano, A. M., Piccini, P. P., Obeso, J. A., Rascol, O., Schapira, A. H. V., Voon, V., et al. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3430 · Cited by 461
Neuropathology underlying clinical variability in patients with synucleinopathies
Halliday, G. M., Holton, J. L., Révész, T., & Dickson, D. W. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0852-9 · Cited by 447
Excessive daytime sleepiness and subsequent development of Parkinson disease
Abbott, R. D., Ross, G. W., White, L. R., Tanner, C. M., Masaki, K., Nelson, J. S., Curb, J. D., & Petrovitch, H. (2005) · Neurology · doi:10.1212/01.wnl.0000183056.89590.0d · Cited by 439
Medical records documentation of constipation preceding Parkinson disease
Savica, R., Carlin, J. M., Grossardt, B. R., Bower, J. H., Ahlskog, J. E., Maraganore, D. M., Bharucha, A. E., & Rocca, W. A. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c34af5 · Cited by 431
Reduced Vesicular Storage of Dopamine Causes Progressive Nigrostriatal Neurodegeneration
Caudle, W. M., Richardson, J. R., Wang, M. Z., Taylor, T. N., Guillot, T. S., McCormack, A. L., Colebrooke, R. E., Monte, D. A. D., Emson, P. C., & Miller, G. W. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.0319-07.2007 · Cited by 389
Alterations of T-lymphocyte populations in Parkinson disease
Baba, Y., Kuroiwa, A., Uitti, R. J., Wszolek, Z. K., & Yamada, T. (2005) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2005.07.005 · Cited by 336
Song, D. D., Shults, C. W., Sisk, A., Rockenstein, E. M., & Masliah, E. (2003) · Experimental Neurology · doi:10.1016/s0014-4886(03)00342-x · Cited by 301
Kuo, Y., Li, Z., Jiao, Y., Gaborit, N., Pani, A. K., Orrison, B. M., Bruneau, B. G., Giasson, B. I., Smeyne, R. J., Gershon, M. D., et al. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq038 · Cited by 289
Behavioral and Neurochemical Effects of Wild-Type and Mutated Human α-Synuclein in Transgenic Mice
Richfield, E. K., Thiruchelvam, M. J., Cory-Slechta, D. A., Wuertzer, C., Gainetdinov, R. R., Caron, M. G., Di Monte, D. A., & Federoff, H. J. (2002) · Experimental Neurology · doi:10.1006/exnr.2002.7882 · Cited by 285
Bordet, T., Buisson, B., Michaud, M., Drouot, C., Galéa, P., Delaage, P., Akentieva, N., Evers, A. S., Covey, D. F., Ostuni, M. A., et al. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.123000 · Cited by 267
Lymphocyte populations in Parkinson's disease and in rat models of parkinsonism
Bas, J. (2001) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(00)00422-7 · Cited by 250
α-Synuclein Overexpression Protects against Paraquat-Induced Neurodegeneration
Manning-Bog, A., McCormack, A. L., Purisai, M. G., Bolin, L. M., & Monte, D. A. D. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-08-03095.2003 · Cited by 242
Hamza, T. H., Chen, H., Hill-Burns, E. M., Rhodes, S. L., Montimurro, J., Kay, D. M., Tenesa, A., Kusel, V. I., Sheehan, P., Eaaswarkhanth, M., et al. (2011) · PLoS Genetics · doi:10.1371/journal.pgen.1002237 · Cited by 218
Neuroinflammation in the living brain of Parkinson's disease
Ouchi, Y., Yagi, S., Yokokura, M., & Sakamoto, M. (2009) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(09)70814-4 · Cited by 210
Olfactory deficits in mice overexpressing human wildtype α‐synuclein
Fleming, S. M., Tetreault, N. A., Mulligan, C. K., Hutson, C. B., Masliah, E., & Chesselet, M. (2008) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2008.06346.x · Cited by 209
Fernagut, P., Hutson, C. B., Fleming, S. M., Tetreaut, N. A., Salcedo, J. D., Masliah, E., & Chesselet, M.-F. (2007) · Synapse · doi:10.1002/syn.20456 · Cited by 202
Enhanced Phosphatase Activity Attenuates α-Synucleinopathy in a Mouse Model
Lee, K.-W., Chen, W. W., Junn, E., Im, J., Grosso, H., Sonsalla, P. K., Feng, X., Ray, N., Fernandez, J. R., Chao, Y., et al. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.6513-10.2011 · Cited by 194
Modelling of Parkinson's disease in mice
Chesselet, M., & Richter, F. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70227-7 · Cited by 190
Circadian dysfunction in a mouse model of Parkinson's disease
Kudo, T., Loh, D. H., Truong, D., Wu, Y., & Colwell, C. S. (2011) · Experimental Neurology · doi:10.1016/j.expneurol.2011.08.003 · Cited by 188
Dopamine Transporter Genetic Variants and Pesticides in Parkinson’s Disease
Ritz, B. R., Manthripragada, A. D., Costello, S., Lincoln, S., Farrer, M. J., Cockburn, M., & Bronstein, J. M. (2009) · Environmental Health Perspectives · doi:10.1289/ehp.0800277 · Cited by 184
Lam, H. A., Wu, N., Cely, I., Kelly, R. L., Hean, S., Richter, F., Magen, I., Cepeda, C., Ackerson, L. C., Walwyn, W., et al. (2011) · Journal of Neuroscience Research · doi:10.1002/jnr.22611 · Cited by 184
Norepinephrine loss produces more profound motor deficits than MPTP treatment in mice
Rommelfanger, K. S., Edwards, G. L., Freeman, K. G., Liles, L. C., Miller, G. W., & Weinshenker, D. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702753104 · Cited by 184
Janvin, C. C., Aarsland, D., & Larsen, J. P. (2005) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988705277540 · Cited by 182
Neuropathology in Mice Expressing Mouse Alpha-Synuclein
Rieker, C., Dev, K. K., Lehnhoff, K., Barbieri, S., Ksiazek, I., Kauffmann, S., Danner, S., Schell, H., Boden, C., Rüegg, M. A., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024834 · Cited by 170
Paraoxonase 1, Agricultural Organophosphate Exposure, and Parkinson Disease
Manthripragada, A. D., Costello, S., Cockburn, M., Bronstein, J. M., & Ritz, B. R. (2009) · Epidemiology · doi:10.1097/ede.0b013e3181c15ec6 · Cited by 169
Epidemiology versus genetics in parkinson's disease: Progress in resolving an age‐old debate
Langston, J. W. (1998) · Annals of Neurology · doi:10.1002/ana.410440707 · Cited by 165
The challenge of non-motor symptoms in Parkinson’s disease
Chaudhuri, К. R., & Odin, P. (2010) · Progress in brain research · doi:10.1016/s0079-6123(10)84017-8 · Cited by 164
Animal models of the non-motor features of Parkinson's disease
McDowell, K. A., & Chesselet, M. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.12.040 · Cited by 158
Wakamatsu, M., Ishii, A., Iwata, S., Sakagami, J., Ukai, Y., Ono, M., Kambe, D., Muramatsu, S., Kobayashi, K., Iwatsubo, T., et al. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.11.017 · Cited by 157
Gait alterations in healthy carriers of the LRRK2 G2019S mutation
Mirelman, A., Gurevich, T., Giladi, N., Bar‐Shira, A., Orr‐Urtreger, A., & Hausdorff, J. M. (2011) · Annals of Neurology · doi:10.1002/ana.22165 · Cited by 149
Genetic mouse models of Parkinson’s disease
Magen, I., & Chesselet, M. (2010) · Progress in brain research · doi:10.1016/s0079-6123(10)84004-x · Cited by 140
TRO40303, a New Cardioprotective Compound, Inhibits Mitochondrial Permeability Transition
Schaller, S., Paradis, S., Ngoh, G. A., Assaly, R., Buisson, B., Drouot, C., Ostuni, M. A., Lacapère, J.-J., Bassissi, F., Bordet, T., et al. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.167486 · Cited by 130
Abnormal colonic motility in mice overexpressing human wild-type α-synuclein
Wang, L., Fleming, S. M., Chesselet, M., & Taché, Y. (2008) · Neuroreport · doi:10.1097/wnr.0b013e3282ffda5e · Cited by 120
-Syn Suppression Reverses Synaptic and Memory Defects in a Mouse Model of Dementia with Lewy Bodies
Lim, Y., Kehm, V. M., Lee, E. B., Soper, J. H., Li, C., Trojanowski, J. Q., & Lee, V. M. Y. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.0618-11.2011 · Cited by 119
Dopamine turnover increases in asymptomatic LRRK2 mutations carriers
Sossi, V., de la Fuente‐Fernández, R., Nandhagopal, R., Schulzer, M., McKenzie, J., Ruth, T. J., Aasly, J. O., Farrer, M. J., Wszołek, Z. K., & Stoessl, A. J. (2010) · Movement Disorders · doi:10.1002/mds.23356 · Cited by 119
Parkinson's disease: a model dilemma
Beal, M. F. (2010) · Nature · doi:10.1038/466s8a · Cited by 114
Koob, A. O., Ubhi, K. K., Paulsson, J. F., Kelly, J. W., Rockenstein, E. M., Mante, M., Adame, A., & Masliah, E. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.11.015 · Cited by 113
Transgenic Models of α‐Synuclein Pathology
Hashimoto, M., Rockenstein, E. M., & Masliah, E. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb07475.x · Cited by 108
Cognitive deficits in a mouse model of pre‐manifest Parkinson’s disease
Magen, I., Fleming, S. M., Zhu, C., Garcia, E. C., Cardiff, K. M., Dinh, D., Rosa, K. D. L., Sánchez, M. Á., Torres, E. R. S., Masliah, E., et al. (2012) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2012.08012.x · Cited by 108
Time to move beyond nigrostriatal dopamine deficiency in Parkinson's disease
Lang, A. E., & Obeso, J. A. (2004) · Annals of Neurology · doi:10.1002/ana.20102 · Cited by 105
Fleming, S. M., Salcedo, J. D., Hutson, C. B., Rockenstein, E. M., Masliah, E., Levine, M. S., & Chesselet, M.-F. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2006.07.005 · Cited by 105
Alterations in corticostriatal synaptic plasticity in mice overexpressing human α-synuclein
Watson, J. B., Hatami, A., David, H., Masliah, E., Roberts, K., Evans, C., & Levine, M. S. (2009) · Neuroscience · doi:10.1016/j.neuroscience.2009.01.021 · Cited by 103
MPTP‐Induced Hypoactivity in Mice: Reversal by L‐Dopa
Fredriksson, A., Płaźnik, A., Sundström, E., JONSSON, G., & Archer, T. (1990) · Pharmacology & Toxicology · doi:10.1111/j.1600-0773.1990.tb00833.x · Cited by 92
Lawal, H. O., Chang, H.-Y., Terrell, A. N., Brooks, E. S., Pulido, D., Simon, A. F., & Krantz, D. E. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.05.008 · Cited by 77
Marxreiter, F., Nuber, S., Kandasamy, M., Klucken, J., Aigner, R., Burgmayer, R., Couillard‐Després, S., Rieß, O., Winkler, J., & Winner, B. (2009) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2009.06641.x · Cited by 77
Bronstein, J. M., Carvey, P. M., Chen, H., Cory‐Slechta, D. A., Monte, D. A. D., Duda, J. E., English, P. B., Goldman, S. M., Grate, S. J., Hansen, J., et al. (2008) · Environmental Health Perspectives · doi:10.1289/ehp.11702 · Cited by 75
Alpha‐synuclein overexpression in mice alters synaptic communication in the corticostriatal pathway
Wu, N., Joshi, P. R., Cepeda, C., Masliah, E., & Levine, M. S. (2009) · Journal of Neuroscience Research · doi:10.1002/jnr.22327 · Cited by 74
Fleming, S. M., Mulligan, C. K., Richter, F., Mortazavi, F., Lemesre, V., Frías, C., Zhu, C., Stewart, A. J., Gozes, I., Morimoto, B. H., et al. (2010) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2010.12.011 · Cited by 72
Clinical neuroprotection in Parkinson's disease — Still waiting for the breakthrough
Löhle, M., & Reichmann, H. (2009) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2009.08.025 · Cited by 70
Toxic effects of dopamine metabolism in Parkinson's disease
Hattori, N., Wang, M., Taka, H., Fujimura, T., Yoritaka, A., Kubo, S., & Mochizuki, H. (2009) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(09)70010-0 · Cited by 67
Regional Distribution of Proteinase K-Resistant α-Synuclein Correlates with Lewy Body Disease Stage
Neumann, M., Müller, V., Kretzschmar, H. A., Haass, C., & Kahle, P. J. (2004) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/63.12.1225 · Cited by 66
α-Synuclein Gene May Interact with Environmental Factors in Increasing Risk of Parkinson’s Disease
Gatto, N. M., Rhodes, S. L., Manthripragada, A. D., Bronstein, J. M., Cockburn, M., Farrer, M. J., & Ritz, B. R. (2010) · Neuroepidemiology · doi:10.1159/000315157 · Cited by 64
Balance is the challenge – The impact of mitochondrial dynamics in Parkinson’s disease
Burbulla, L. F., Krebiehl, G., & Krüger, R. (2010) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2010.02354.x · Cited by 46
Neurotrophins and cytokines in Parkinson's disease.
Mogi, M., & Nagatsu, T. (1999) · PubMed · Cited by 42
Transgenic animal models of neurodegeneration based on human genetic studies
Harvey, B. K., Richie, C. T., Hoffer, B. J., & Airavaara, M. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0476-6 · Cited by 38
Delfs, J. M., Ciaramitaro, V. M., Soghomonian, J., & Chesselet, M. (1996) · Neuroscience · doi:10.1016/0306-4522(95)00470-x · Cited by 31
Targeting Neuroprotection as an Alternative Approach to Preventing and Treating Neuropathic Pain
Bordet, T., & Pruss, R. M. (2009) · Neurotherapeutics · doi:10.1016/j.nurt.2009.07.001 · Cited by 24
Behavioural and neurochemical response of α-synuclein A30P transgenic mice to the effects of L-DOPA
Oksman, M., Tanila, H., & Yavich, L. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.11.004 · Cited by 22
Dopamine and Parkinson's disease: is the killer in the house?
Chesselet, M. (2003) · Molecular Psychiatry · doi:10.1038/sj.mp.4001289 · Cited by 21
Mouse Models of Cognitive Deficits Due to Alpha-Synuclein Pathology
Magen, I., & Chesselet, M. (2011) · Journal of Parkinson s Disease · doi:10.3233/jpd-2011-11043 · Cited by 20
Interaction between α-Synuclein and Tau Genotypes and the Progression of Parkinson's Disease
Huang, Y. M., Rowe, D. B., & Halliday, G. M. (2011) · Journal of Parkinson s Disease · doi:10.3233/jpd-2011-11027 · Cited by 17
Mochizuki‐Kawai, H., Mochizuki, S., & Kawamura, M. (2009) · Experimental Brain Research · doi:10.1007/s00221-009-2119-4 · Cited by 17
Research works printed but not linked: 6
- Hean, 2010, Mice overexpressing human alpha synuclein (Thy1-aSyn) show dopamine loss, catalepsy and severe motor deficits partially rescued by L-DOPA at 14 months of age, Neurosci Abstr, 750
- Torres, 2010, Mice overexpressing human alpha synuclein under the Thy1-promotor show increased fear conditioning and altered responses in anxiety related behavior, Neurosci Abstr, 750
- Mulligan, 2008, Mice overexpressing human wildtype alpha-synuclein under the Thy-1 promoter exhibit anomalies in behavioral tests of anxiety, Neurosci Abstr, 742
- Richter, 2011, Transcriptome network and pathway analyses reveal early alterations in dopaminergic neurons of mice overexpressing human wild-type alpha-synuclein (Thy1-aSyn), Neurosci Abstr, 357
- Richter, 2010, The cholesterol-oximes TRO19622 and TRO40303 affect motor function, olfaction, and alpha synuclein aggregation in mice overexpressing human alpha synuclein under the Thy1 promoter, Neurosci Abstr, 750
- Lemesre, 2010, The glucocerebrosidase pharmacological chaperone afegostat-tartrate (AT2101) partially improves motor and olfactory function and alters the size of alpha-synuclein inclusions in mice overexpressing alpha-synuclein, Neurosci Abstr, 750
Cited by
Sorted by citations
Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease
Sampson, T. R., Debelius, J. W., Thron, T., Janssen, S., Shastri, G. G., Ilhan, Z. E., Challis, C., Schretter, C. E., Rocha, S., Gradinaru, V., et al. (2016) · Cell · doi:10.1016/j.cell.2016.11.018 · Cited by 3,622
Mitochondrial dysfunction and oxidative stress in Parkinson's disease
Subramaniam, S., & Chesselet, M. (2013) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.04.004 · Cited by 953
Neuroinflammation in Parkinson's disease and its potential as therapeutic target
Wang, Q., Liu, Y., & Zhou, J. (2015) · Translational Neurodegeneration · doi:10.1186/s40035-015-0042-0 · Cited by 884
The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology
Rutsch, A., Kantsjö, J. B., & Ronchi, F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.604179 · Cited by 821
A gut bacterial amyloid promotes α-synuclein aggregation and motor impairment in mice
Sampson, T. R., Challis, C., Jain, N., Moiseyenko, A., Ladinsky, M. S., Shastri, G. G., Thron, T., Needham, B. D., Horvath, I., Debelius, J. W., et al. (2020) · eLife · doi:10.7554/elife.53111 · Cited by 439
Metadata
- Authors
- Chesselet, M.-F., Richter, F., Zhu, C., Magen, I., Watson, M. B., & Subramaniam, S. R.
- Affiliations
- University of California, Los Angeles (US)
- Venue
- Neurotherapeutics
- Publisher
- Elsevier BV
- Published
- 2012-04
- Volume
- 9
- Issue
- 2
- Pages
- 297-314
- ISSN
- 1878-7479 (ISSN-L)
- PMC
- PMC3337020
- OpenAlex
- W2169324918
- Cited by
- 346
- References
- 88
- Citations by year
- 2026: 18 · 2025: 38 · 2024: 38 · 2023: 30 · 2022: 33 · 2021: 40 · 2020: 23 · 2019: 20 · 2018: 26 · 2017: 26 · 2016: 12 · 2015: 13 · 2014: 21 · 2013: 5 · 2012: 3
- FWCI
- 1.88
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Neurotherapeutics (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Neurological Disorders and Stroke (P50-NS 38367, P50NS038367)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Keywords
- Parkinson's disease, alpha-synuclein, mouse model, sporadic Parkinson's disease, dopamine release, striatum, motor impairment, neuroinflammation, neuroprotection, preclinical drug testing, alpha-synuclein pathology
- MeSH terms
- Animals, Disease Models, Animal, Humans, Mice, Neurologic Mutants, Parkinson Disease, Promoter Regions, Genetic, Disease Progression, Mice, alpha-Synuclein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
